View source for Tebanicline

{{Drugbox
|IUPAC_name = 5-([(2R)-azetidin- 2-yl] methoxy)- 2-chloropyridine
| image=Tebaniciclina.png
| width= 240
| CAS_number= 198283-73-7
| ATC_prefix= none
| ATC_suffix= 
| PubChem= 3075702
| DrugBank=
| C=9 | H=11 | Cl=1 | N=2 | O=1
| molecular_weight = 198.649
| smiles = C1CN[C@H]1COC2=CN=C(C=C2)Cl
| bioavailability=
| metabolism =
| elimination_half-life=
| excretion =
| pregnancy_category =
| legal_status =
| routes_of_administration= 
}}

'''Tebanicline''' ('''Ebanicline''', '''ABT-594''') is a drug developed by [[Abbott Laboratories|Abbott]], which acts as a [[partial agonist]] at neuronal [[nicotinic acetylcholine receptor]]s, binding to both the [[ganglion type nicotinic receptor|α3β4]] and the [[Alpha-4 beta-2 nicotinic receptor|α4β2]] [[nicotinic acetylcholine receptor#Subunits|subtypes]].<ref>{{Cite pmid|14983978}}</ref> It was developed as a less toxic analogue of the potent frog-derived compound [[epibatidine]], which is some 200x stronger than [[morphine]] as an [[analgesic]] but produces extremely dangerous toxic side effects.<ref>{{Cite pmid|9417028}}</ref><ref>{{Cite pmid|9484491}}</ref> Like epibatidine, tebanicline showed potent analgesic activity against [[neuropathic pain]] in both animal and human trials, but with far less toxicity than its parent compound.<ref>{{Cite pmid|9580626}}</ref><ref>{{Cite pmid|9580627}}</ref><ref>{{Cite pmid|9617748}}</ref><ref>{{Cite pmid|10779668}}</ref><ref>Sorbera LA, Revel L, Leeson PA, Castaner J. ABT-594. ''Drugs Future'' 2001; 26: 927-934).</ref><ref>{{Cite pmid|15713428}}</ref>

Tebanicline got as far as Phase II trials in humans,<ref>{{Cite pmid|11772288}}</ref> but was dropped from further development due to unacceptable incidence of gastrointestinal side effects.<ref>Meyer MD. Neuronal Nicotinic Acetylcholine Receptors as a Target for the Treatment of Neuropathic Pain. ''Drug Development Research''. 2006; 67: 355-359.</ref> However further research in this area is ongoing,<ref>{{Cite pmid|15745813}}</ref><ref>{{Cite pmid|16412637}}</ref><ref>{{Cite pmid|17585748}}</ref><ref>{{Cite pmid|18088559}}</ref> and it is expected that development of new neural nicotinic acetylcholine receptor agonists will be likely to lead to novel analgesics suitable for use in humans within the next few years.<ref>Lloyd GK, Williams M. Neuronal Nicotinic Acetylcholine Receptors as Novel Drug Targets. ''Journal of Pharmacology and Experimental Therapeutics''. 2000; 292:461-467.</ref><ref>{{Cite pmid|16185161}}</ref><ref>{{Cite pmid|17662959}}</ref><ref>{{Cite pmid|18508600}}</ref>

== References ==
{{Reflist|2}}


{{Stimulants}}
{{Analgesics}}
{{Nootropics}}
{{Cholinergics}}



[[Category:Analgesics]]
[[Category:Pyridines]]
[[Category:Nicotinic agonists]]
[[Category:Stimulants]]
[[Category:Organochlorides]]
[[Category:Phenol ethers]]
[[Category:Azetidines]]


{{analgesic-stub}}

[[es:Tebaniciclina]]
[[Category:2Fix]]